We present a case of ischaemic stroke in a 23-year-old woman, associated with homozygous methylene tetrahydrofolate reductase (MTHFR)-C677T and hyperhomocysteinaemia. Her other risk factors for stroke were ostium secundum atrial septal defect and use of oral contraceptives. This case illustrates the need to include plasma homocysteine (Hcy) measurement in investigations following stroke. In the presence of hyperhomocysteinaemia, the MTHFR genotype should be determined. If the index case has the polymorphism, then all rst-degree relatives should also be investigated by measurement of plasma Hcy and determination of MTHFR genotype.
A 23-year-old Caucasian woman was admitted to hospital with sudden-onset history of speech loss and right-sided weakness. During the preceding 2 weeks she had felt unwell and had had word-¢nding di¤culties. Past medical history included asthma, hay fever and umbilical hernia repair. She was taking a combined oral contraceptive (Eugynon 30) therapy and a salbutamol inhaler. Her paternal grandfather and maternal grandmother had had strokes at ages 65 and 80 years, respectively. A maternal aunt had had folate de¢ciency.
On clinical examination, blood pressure was 120/ 60 mmHg, pulse was regular at 80/min and the Glasgow coma scale was 10/15. Power was abolished in the right arm and decreased in the right leg, in keeping with the diagnosis of cerebrovascular accident.
Full haematological (including thrombophilia screen), immunological and biochemical laboratory investigations were all within normal limits, except for plasma total homocysteine concentration (tHcy), which was measured on day 2 of admission and was elevated to 46.3 mmol/L (normal range 5^15), with normal plasma cysteine and methionine concentrations. Urine homocysteine concentration and organic acid screen were normal.
Carotid doppler ultrasound was normal. Brain magnetic resonance imaging (MRI) showed a left middle cerebral artery (MCA) infarct, and a thrombus was observed within the left MCA on magnetic resonance angiography.
Once oral intake was considered safe, therapy with aspirin (300 mg/day) and dipyridamole (200 mg twice daily) was initiated. On day 14, after samples were taken for serum folate, vitamin B12 and vitamin B6 concentrations, the patient was commenced on folate 5 mg, cyanocobalamin 50 mg and pyridoxine 50 mg, all daily. Table 1 shows baseline and subsequent measurements of homocysteine, folate, vitamin B12 and vitamin B6 concentrations. The patient was discharged after 21 days of hospitalization.
An ostium secundum atrial septal defect was diagnosed on transoesophageal echocardiography 40 days later. Closure of the foramen ovale was performed 8 months later and aspirin 150 mg/day and clopidogrel 75 mg/day prescribed. The patient and her ¢rst-degree relatives were investigated for methylene tetrahydrofolate reductase (MTHFR)-C677T polymorphism. The patient, her mother and two sisters were all homozygous and her father was heterozygous. In one sister plasma tHcy concentration was increased to 63.0 mmol/L with slightly raised urine homocysteine concentration; she was also commenced on folate and vitamin B12. Baseline tHcy, folate, vitamin B12 and vitamin B6 concentrations in the ¢rst-degree relatives are shown in Table 2 .
Discussion
Homocysteine is a sulphur-containing amino acid derived from dietary methionine by demethylation. The remethylation pathway requires the MTHFR enzyme and converts 5,10-methylene tetrahydrofolate to 5-methyltetrahydrofolate. A single pair substitution (C-to-T) at base 677 of the gene that encodes the MTHFR is common. A prevalence of approximately 10% has been described in its homozygous form, which is associated with a 50% reduction of the activity of the enzyme, 1 a raised plasma homocysteine concentration 2 and a reduced folate concentration. 3 The prevalence of the MTHFR-677TT genotype among controls ranges from *1% in Blacks 4 and 3.2% in UK Indian Asians 5 to 12% in Caucasians 6 and 30.2% in Italians. 7 The MTHFR-677TT genotype is associated with increased atherosclerotic risk only when folate status is low, which indicates an interaction between this polymorphism and folate status. At high dietary intakes of folate, the e¡ect of the polymorphism has no adverse e¡ect on plasma homocysteine concentrations or on subsequent atherosclerosis risk. The polymorphis m is signi¢cantly associated with a 14% increase in coronary heart disease (CHD) risk in European populations but not in North American populations because of folate forti¢cation of cereals in the latter continent. 8 Folate concentrations have increased and plasma Hcy concentrations have reduced in the US population. 9 Ischaemic stroke has a prevalence of 3^5% among young adults. 10, 11 A meta-analysis of case^control and prospective studies indicated that moderate hyperhomocysteinaemia confers at least a 2.5-fold increased risk of stroke. 12 The MTHFR-677TT mutation is associated with raised plasma tHcy concentrations in children and is a risk factor for primary and secondary stroke and transient ischaemic attack. 13 One study in older patients showed a strong association between increasing plasma tHcy concentration and ischaemic stroke caused by atherosclerosis; paradoxically, no association was found with the MTHFR genotype. 14 One potential explanation is that the majority of studies lacked su¤cient power to detect an association. 15 Epidemiological studies have correlated homocysteine concentration and the MTHFR mutation with all types of stroke but not with aetiologic subtypes of stroke, and this could also have contributed to the inconsistent ¢ndings.
Ischaemic stroke among young patients is a multifactorial disease in which inherited predisposing factors play an increasingly relevant role. The interaction of inherited factors with environmental variables (e.g. folate intake) may be an important determinant of propensity to develop stroke events. 12 Experimental studies suggest that homocysteine promotes atherogenesis by facilitating oxidative arterial injury, damaging the vascular matrix and increasing proliferation of vascular smooth muscle. It may promote thrombo-embolic disease by causing oxidative injury to the endothelium, altering the coagulant properties of the blood, and impairing endothelium-dependent vasomotor regulation. 16 Plasma homocysteine concentration has been variously reported as being 2.5 mmol/L higher 2 and *25% higher 1, 17 in MTHFR-677TT genotype individuals compared with 677CC genotype individuals. The patient presented had plasma tHcy concentrations 4.5-fold greater than her heterozygous father, *6.5fold greater than her homozygous mother and one of her homozygous sisters, and 27.5 % less than her other homozygous sister. This shows that not all persons homozygous for the mutation have an increased plasma tHcy concentration. This could be due to a di¡erent penetrance of the mutation, leading to di¡erent degrees of enzyme de¢ciency, and/or due to the e¡ect of dietary folate on plasma tHcy. The two described homozygous subjects with intermediate hyperhomocysteinaemia (i.e. 31^100 mmol/L, as categorized by the American Heart Association) 18 had an inadequate intake of fruit and vegetables, whereas the other two homozygotes with normal plasma tHcy concentrations had a high intake. This agrees with a previous statement that many homozygous individuals may have normal homocysteine concentrations but in the presence of suboptimal folate intake may develop hyperhomocysteinaemia. 6 At a high folate intake there is no association with the polymorphism and risk of CHD. 8 Had this family not been screened, we would have missed one case with moderate hyperhomocysteinaemia which potentially could have caused thrombosis. Measurement of plasma tHcy concentration should be included amongst the investigations following premature stroke. In the presence of hyperhomocysteinaemia, the MTHFR genotype should be determined. If the C677T mutation is identi¢ed, all ¢rst-degree relatives should also be investigated and treated.
Vitamin therapy in the index case showed a greater reduction in plasma tHcy concentration (90%) than has previously been reported (23^38%), possibly due to the greatly increased pre-treatment plasma tHcy concentration. More marked reductions in plasma tHcy concentration have been shown following folic acid supplementation where pre-treatment plasma tHcy concentration is greater and pre-treatment serum folate concentration is less. 19 The assessment of plasma Hcy concentration as a cardiovascular risk factor was recently reviewed. 20 Results from large randomized trials of the e¡ects on vascular disease of reducing Hcy concentration with folic acid-based vitamin supplementation should provide information about the relevance of plasma Hcy concentration to the risk of atherosclerotic disease.
Stroke is polygenic in aetiology, and it is possible that hyperhomocysteinaemia, a patent foramen ovale and oral contraceptive therapy all contributed to the case presented here. The patient's family history of stroke might have played a minor role. Hyperhomocysteinaemia was probably due to the association of homozygosity for the MTHFR-C677T polymorphism and low folate intake.
Prevention is a promising strategy to reduce the worldwide burden of stroke, and folate forti¢cation of food may be part of this strategy.
